International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 5 , Pages 1323-1331, 1 April 2007

A Phase II Multi-institutional Trial of Chemoradiation Using Weekly Docetaxel and Erythropoietin for High-Risk Postoperative Head and Neck Cancer Patients

The results of this study were previously presented at the 2004 American Society of Clinical Oncology meeting.

  • Christopher D. Willey, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Barbara A. Murphy, M.D.

      Affiliations

    • Department of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • James L. Netterville, M.D.

      Affiliations

    • Department of Otolaryngology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Brian B. Burkey, M.D.

      Affiliations

    • Department of Otolaryngology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Yu Shyr, Ph.D.

      Affiliations

    • Department of Head and Neck Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Bashar Shakhtour, B.S.

      Affiliations

    • Department of Head and Neck Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Bonnie Kish, R.N.

      Affiliations

    • Department of Biostatistics, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • David Raben, M.D.

      Affiliations

    • Department of Clinical Trials Office, Vanderbilt University Medical Center, Nashville, Tennessee
    • ,
  • Changhu Chen, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • ,
  • John I. Song, M.D.

      Affiliations

    • Department of Otolaryngology, University of Colorado Health Sciences Center, Denver, Colorado
    • ,
  • Madeleine A. Kane, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • ,
  • Anthony J. Cmelak, M.D.

      Affiliations

    • Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • Corresponding Author InformationReprint requests to: Anthony J. Cmelak, M.D., Radiation Oncology, Vanderbilt-Ingram Cancer Center, B-902, The Vanderbilt Clinic, Nashville, TN 37232-5671. Tel: (615) 343-9462; Fax: (615) 343-0161

Received 11 September 2006; received in revised form 14 November 2006; accepted 17 November 2006. published online 07 February 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This research was supported by Sanofi Aventis.Conflict of interest: none.

PII: S0360-3016(06)03504-8

doi:10.1016/j.ijrobp.2006.11.033

International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 5 , Pages 1323-1331, 1 April 2007

Article Tools

* Image Usage & Resolution